Sotera Health Company 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter revenue increased 4.4% to $325 million, both as reported and on a constant currency basis, versus the third quarter of 2025.
- GAAP net income was $58 million, or 20 cents per diluted share; adjusted EBITDA increased 3.9% to $171 million, or 4% on a constant currency basis.
- Adjusted EBITDA margin expanded sequentially by nearly 100 basis points to 52.5%; year-to-date adjusted EBITDA margin was up 8 basis points.
- Adjusted EPS increased 12% year over year to 29 cents per diluted share, and interest expense was $34 million, a $5 million improvement versus the prior-year period.
- Sterogenics revenue increased 8.5% to $209 million, or 8.2% on a constant currency basis; segment income increased 9.6% to $117 million, and segment income margin rose 57 basis points to 56.1%.
- Nelson Labs revenue increased 8.8% to $61 million, or 9.2% on a constant currency basis; segment income rose 2.5% to $19 million, while segment income margin declined 199 basis points to 32.1%, primarily due to business mix.
- Norion revenue declined 12.4% to $55 million, or 11.5% on a constant currency basis, reflecting lower volume mix and shipment timing; segment income decreased 11.4% to approximately $34 million, while segment income margin improved 71 basis points to 61.3%.
- Year-to-date operating cash flow was $228 million, including $111 million in Q3; capital expenditures were $145 million for the first nine months, including $53 million in Q3.
- Net leverage was 2.9 times as of September 30 of 2026, within the long-term target range of 2 to 3 times; Moody's upgraded the company's credit rating in early October.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Sotera Health third quarter 2026 conference call. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw from the question queue, you may press star then two. Please note, this event is being recorded. I would now like to turn the conference call over to Vice President of Investor Relations, Mr. Jason Peterson. Mr. Peterson, the floor is yours, sir.
Good morning, and welcome to Sotera Health's third quarter earnings call. Today's press release and earnings presentation are available on the investor section of our website at soterahealth.com. This webcast is being recorded, and a replay will also be available on the investor section of the Sotera Health website shortly after the call. Joining me today are Chief Executive Officer, Alton Shader, Chief Financial Officer, Jon Lyons, and Executive Chairman, Michael Petras. During today's call, some of our comments may be considered forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to Sotera Health's SEC filings and the forward-looking statement slide at the beginning of the earnings presentation for a description of these risks and uncertainties. The company assumes no obligation to update any such forward-looking statements.
Please note that during the discussion today, the company will present both GAAP and non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, tax rate applicable to adjusted net income, adjusted net income, adjusted EPS, net debt, and net leverage ratio, as well as constant currency comparisons. A reconciliation of GAAP to non-GAAP measures for all relevant historical periods may be found in the schedules attached to the company's press release and in the supplemental slides to the earnings presentation. The operator will be assisting with the Q&A portion of the call today. Please limit yourself to one question and one follow-up. For further questions, feel free to reach out to the investor relations team. I will now turn the call over to Sotera Health CEO, Alton Shader.
Good morning, and thank you for joining us. Today, we reported solid top and bottom line growth versus the third quarter of 2025, driven by strong execution and sequential adjusted EBITDA margin improvement of nearly 100 basis points. For the third quarter, we delivered constant currency revenue growth of 4.4% and constant currency adjusted EBITDA growth of 4% versus the same period last year. Sterigenics continued to perform well, generating 8.2% constant currency revenue growth and 57 basis points of segment income margin expansion, despite experiencing some softness in the med device market during the quarter, which has continued into the early part of Q4. Nelson Labs delivered another strong quarter, with revenue increasing 9.2% on a constant currency basis, as the team continued to execute on complex projects to support our customers' regulatory needs. As expected, Nordion results reflected the timing of cobalt-60 harvest schedules.
The Nordion team did a great job delivering critical cobalt-60 shipments for their customers and expanded segment income margins by 71 basis points. Based on our year-to-date performance and our current visibility into the remainder of the year, we are reaffirming our constant currency revenue and adjusted EBITDA outlook for 2026. At Sotera Health, we work tirelessly to help ensure the safety and availability of healthcare products that millions of patients rely on every day. Before Jon reviews the financials in more detail, I want to provide some additional context around an example we shared on our second quarter call that highlights how our teams make a meaningful difference for customers and patients. As we've discussed previously, customers regularly turn to Nelson Labs when they face time-sensitive and complex challenges.
During the second and third quarters, a customer of ours faced an urgent regulatory testing need involving a product used in a significant percentage of surgeries performed around the world. The Nelson Labs team quickly mobilized its scientific and technical expertise, completed the required testing on an accelerated timeline, and helped the customer maintain the availability of a critical healthcare product. While this was one project, the impact was far broader. By helping our customer address a time-sensitive challenge, our team played an important role in supporting tens of millions of patients who rely on these critical medical procedures. This is exactly what we mean when we talk about putting customers first and delivering on our mission of safeguarding global health. I will now hand it off to Jon, who will walk us through the financials.
Thank you, Alton. I'll begin with an overview of our consolidated financial results, followed by performance highlights from each of our business segments. I'll then review the balance sheet, cash generation, and capital allocation before concluding with an update on our 2026 outlook. On a consolidated total company basis, third quarter revenues increased 4.4% on both an as-reported and constant currency basis to $325 million as compared to the third quarter of 2025. Net income on a GAAP basis for the quarter was $58 million, or $0.20 per diluted share. Adjusted EBITDA improved by 3.9% to $171 million, or 4% on a constant currency basis. Adjusted EBITDA margins expanded sequentially by nearly 100 basis points to 52.5%. On a year-to-date basis, adjusted EBITDA margins were up 8 basis points.
Interest expense for the third quarter was $34 million, a $5 million improvement versus the prior year period, driven by our repricing actions and last year's $75 million term loan paydown. Adjusted EPS increased to $0.29 per diluted share, an improvement of 12% versus the prior year. Now let's review our segment performance. Sterigenics delivered revenue growth of 8.5% to $209 million, or 8.2% on a constant currency basis, driven by favorable pricing of 4.8%, increased volume and mix of 3.4%, and a foreign currency benefit of 30 basis points. Segment income increased 9.6% to $117 million, or 9.2% on a constant currency basis, reflecting continued operating leverage and strong execution. Segment income margin improved 57 basis points year over year to 56.1%. In Nelson Labs, revenue grew 8.8% to $61 million, or 9.2% on a constant currency basis.
Growth was driven by strong volume mix of 6.6% and favorable pricing of 2.6%, partially offset by a 40 basis point foreign currency headwind. Revenue growth exceeded expectations as we saw an increase in expert advisory services activity in the quarter. Nelson Labs segment income rose 2.5% to $19 million, or 3% on a constant currency basis. Segment income margin declined 199 basis points to 32.1%, driven primarily by business mix. Nordion's third quarter revenue was $55 million, down 12.4% or 11.5% on a constant currency basis. Favorable pricing of 2.2% was offset by a volume mix decline of 13.7% and a foreign currency headwind of 90 basis points. I would also like to mention that although Nordion's revenue was down for the quarter, it did come in ahead of our expectations, driven by earlier than anticipated timing of certain shipments.
Nordion's segment income decreased 11.4% to approximately $34 million, or 10.4% on a constant currency basis. Margin performance remained strong, with segment income margin improving 71 basis points versus Q3 2025 to 61.3%, driven by operational productivity and favorable pricing. Turning to the balance sheet, cash generation, and capital deployment. Year to date, we have generated $228 million in operating cash flow, including $111 million in Q3, demonstrating solid generation during the period. Capital expenditures totaled $145 million during the first nine months of the year, including $53 million in the third quarter, supporting Sterigenics capacity expansions and EO facility upgrades, Nordion cobalt-60 development initiatives, and the completion of a new state-of-the-art clean room at our Salt Lake City lab. We continue to make great progress strengthening our balance sheet.
Net leverage improved to 2.9 times as of September 30th, 2026, within our long-term target range of 2-3 times. This progress was recognized with a credit rating upgrade from Moody's in early October. Now I'd like to turn to our 2026 full year outlook. As Alton mentioned, we are maintaining our 2026 revenue outlook of 5.25%-6.75% constant currency growth, with reported revenue in the range of $1.233 billion-$1.250 billion. We also remain confident in our full year adjusted EBITDA outlook of 5.75%-7.25% constant currency growth, with adjusted EBITDA in the range of $632 million-$641 million. These reported ranges incorporate an estimated 70 basis point foreign currency benefit for the full year, with foreign exchange anticipated to be a headwind of more than 100 basis points in the fourth quarter.
We expect full year consolidated adjusted EBITDA margins to be approximately flat versus last year, with anticipated margin expansion at Sterigenics and Nordion offsetting a reduction in Nelson Labs. Our outlook continues to assume total company pricing for 2026 to be within our long-term range, 3%-4%. We continue to expect Sterigenics to deliver mid to high single digit constant currency revenue growth in 2026. Reflecting recent softness we have seen in the med device market, fourth quarter constant currency revenue growth is anticipated to be approximately 6%. At Nordion, we now expect full year constant currency revenue growth in the mid-single digits, supported by year-to-date performance and our demand expectations through year-end. At Nelson Labs, based on our year-to-date performance, we now expect full year 2026 constant currency revenue growth in the low to mid-single digits.
As we look to the fourth quarter, we expect growth to moderate from third quarter levels while continuing to benefit from the previously mentioned expert advisory services activity. We now project full year segment income margins to be similar to year-to-date levels. Turning to several other assumptions underlying our outlook. Based on market rates, we are narrowing our 2026 interest expense outlook to a range of $137 million-$140 million. Our effective tax rate applicable to adjusted net income remains unchanged at 27%-28%. We anticipate depreciation expense to increase in 2026 modestly above the increase experienced in 2025. On a weighted average basis, we continue to expect a fully diluted share count in the range of 289 million-291 million shares.
Taking these factors into account, we expect to remain on track to deliver adjusted EPS of $0.95 to $1.01 per diluted share in 2026. Capital expenditures are anticipated to be in the $200 million-$225 million range. We continue to expect net leverage ratio improvement compared to 2025. Finally, as usual, our outlook does not assume any M&A activity. I'll now turn the call back over to Alton.
Thank you, Jon. We're pleased with our performance through the first three quarters of the year and remain focused on executing against our priorities. I continue to be impressed with our team's focus on delivering for our customers and the essential nature of our offerings across the company. With that, operator, let's open the line for questions.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
